A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab
This study makes a significant contribution to the field by emphasizing the importance of long-term monitoring of approved agents to further expand on potential adverse events and to distinguish between events that are disease-related versus those more directly related to the particular treatment.
Authors
- Min Wu (ORCID: https://orcid.org/0000-0001-6640-5826)
- Xinlei Zheng (ORCID: https://orcid.org/0000-0003-3271-6903)
- Qichun Nian
- Yan Chen (ORCID: https://orcid.org/0000-0002-1397-6358)
- Yu Lin
- Maohua Chen (ORCID: https://orcid.org/0000-0002-0812-2729)
- Li Lin
Institutions
- Fujian Medical University (CN)
- Zhejiang Center for Disease Control and Prevention (CN)
- Fujian Provincial Hospital (CN)
- Pingliang People's Hospital (CN)
- Union Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1080/14740338.2024.2441286
- Citations
- 3
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 2.13